Analysts Offer Insights on Healthcare Companies: Novavax (NVAX) and DENTSPLY SIRONA (XRAY)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Novavax (NVAX – Research Report) and DENTSPLY SIRONA (XRAY – Research Report).
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Novavax (NVAX)
Bank of America Securities analyst Alec Stranahan reiterated a Sell rating on Novavax today and set a price target of $6.00. The company’s shares closed last Thursday at $6.68, close to its 52-week low of $3.81.
According to TipRanks.com, Stranahan is a 3-star analyst with an average return of
Currently, the analyst consensus on Novavax is a Hold with an average price target of $10.00.
See Insiders’ Hot Stocks on TipRanks >>
DENTSPLY SIRONA (XRAY)
In a report released today, Lilia-Celine (Lily) Lozada from J.P. Morgan reiterated a Hold rating on DENTSPLY SIRONA. The company’s shares closed last Thursday at $11.28.
According to TipRanks.com, Lozada is a 2-star analyst with an average return of
Currently, the analyst consensus on DENTSPLY SIRONA is a Hold with an average price target of $13.27, which is a 15.2% upside from current levels. In a report issued on December 16, Robert W. Baird also maintained a Hold rating on the stock with a $12.00 price target.
